News

Y-mAbs Therapeutics to Share Key Updates in Upcoming Call

Y-mAbs Therapeutics to Share Key Updates in Upcoming Call

Y-mAbs Therapeutics Plans Conference Call for Q3 Results

Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), a leading biopharmaceutical company, has announced an important upcoming conference call. The call will take place on November 8, 2024, prior to the market opening. This event aims to provide investors and stakeholders with insights into their financial and operational performance for the third quarter of 2024.

Details of the Upcoming Conference Call

During this conference call, Y-mAbs will delve into its financial results and provide updates on operations. The call is slated for 8:00 a.m. EST, allowing participants to join and learn more about the company’s ongoing progress and future strategies.

How to Participate

Investors interested in joining the call can dial in using the following numbers: for domestic listeners, the number is (877) 407-0792, while international callers can reach the conference at (201) 689-8263. This is an excellent opportunity for stakeholders to hear directly from Y-mAbs leadership about the company’s trajectory and plans.

About Y-mAbs Therapeutics, Inc.

Y-mAbs is recognized for its commitment to developing innovative therapies to address cancer treatment. The firm specializes in radioimmunotherapy and antibody-based drugs, harnessing cutting-edge technology to advance treatment options. One of their flagship products, DANYELZA® (naxitamab-gqgk), has made significant strides as the first FDA-approved therapy for patients with relapsed or refractory high-risk neuroblastoma.

Innovative Technology and Products

The company’s pioneering technologies, including the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT), exemplify its dedication to transforming cancer care. By utilizing these innovative platforms, Y-mAbs continues to expand its product pipeline, focusing on therapies that offer hope to patients facing serious challenges in treatment.

Investor Relations and Company Information

For those seeking more information about the company, Y-mAbs maintains a robust investor relations program. The VP, Head of Investor Relations, Courtney Dugan, is readily available for inquiries. Interested parties can reach out via email at cdu@ymabs.com. This ensures that investors have access to the latest updates and valuable insights about the company's performance and future endeavors.

Commitment to Transparency

Y-mAbs prides itself on transparency and regular communication with its stakeholders. The upcoming conference call is a testament to this commitment, allowing for an open dialog regarding its financial health and the innovative steps being taken in the fight against cancer.

Frequently Asked Questions

What is the purpose of the upcoming conference call?

The conference call is intended to share Y-mAbs' third quarter 2024 financial and operational results with investors and stakeholders.

When will Y-mAbs hold the conference call?

The call is scheduled for November 8, 2024, at 8:00 a.m. EST.

How can investors join the conference call?

Investors can participate by dialing (877) 407-0792 for domestic calls and (201) 689-8263 for international calls.

What products are highlighted by Y-mAbs?

Y-mAbs highlights its anti-GD2 therapy DANYELZA®, which is FDA-approved for treating relapsed or refractory high-risk neuroblastoma.

Who can investors contact for more information?

Investors can contact Courtney Dugan, VP of Investor Relations, via email at cdu@ymabs.com for further inquiries.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 4

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading

Top 5 Most Recently Viewed Articles

Singapore's Economic Outlook: Growth Prospects for 2024 & 2025

Updated Category News Views 803

Singapore's Economic Forecast for 2024 and 2025 In a recent announcement, Singapore's central bank provided insights into the nation's economic growth forecasts for the upcoming years. The Monetary Authority of Singapore (MAS) indicated that it anticipates GDP growth to reach the upper end of the 2%-3% range for both 2024 and 2025. This clarion call reflects a positive...

Continue Reading
How Communities In Schools Transforms Student Success and Futures

Updated Category News Views 105

Transforming Academic Success Through Integrated Supports Communities In Schools (CIS) has long been recognized as a powerful force in education, providing essential integrated student supports to K-12 schools. A recent landmark study has shed light on the profound impact of such initiatives in promoting academic success and enhancing long-term economic mobility for...

Continue Reading
Exoticca Secures €25M Venture Debt, Expands Global Travel Tech

Updated Category News Views 447

Exoticca Secures €25 Million in Venture Debt from BBVA Spark Exoticca, the leading travel tech platform known for its multi-day tour packages, has announced a significant financial boost with the acquisition of a €25 million venture debt facility from BBVA Spark. This latest funding follows on the heels of the company’s previous €60 million raised during its...

Continue Reading
JPMorgan's Recent Downgrade and What It Means for Hertz

Updated Category News Views 150

JPMorgan Downgrades Hertz Stock: An Overview Recently, Hertz Global Holdings, Inc. (NASDAQ: HTZ) has been in the spotlight after JPMorgan made a significant change in its stock rating. The firm downgraded Hertz from Neutral to Underweight, casting doubts on the company's future performance due to a confluence of factors affecting the travel and automotive sectors. This...

Continue Reading
Empowering Future Scholars in Parkinson's Movement Disorders

Updated Category News Views 171

Investing in Parkinson's Research Through Fellowship The Edmond J. Safra Fellowship in Movement Disorders has made a remarkable impact since its inception in 2014. With over 48 graduates specializing in movement disorders worldwide, the program is set to train 17 more specialists, ultimately aiming for a total of 103 by 2031. This initiative is crucial, as it seeks to...

Continue Reading